Dr. Stuart Turvey

Head of Host Defense, CUPIC

Co-Director, Immunity in Health & Disease Research Cluster

Clinical Scientist, CFRI
Assistant Professor, Division of Infectious and Immunological Diseases, Department of Pediatrics, University of British Columbia

Dr. Stuart Turvey joined the UBC Department of Pediatrics as a clinician-scientist in July 2004. Prior to coming to Vancouver, Stuart completed both his Pediatric Residency and Allergy/Immunology Fellowship at Children's Hospital, Harvard Medical School, Boston. Stuart holds a medical degree (MB BS) from the University of Sydney, Australia and a doctorate (DPhil) in Immunology from Oxford University where he was a Rhodes Scholar. Dr. Turvey is a Fellow of the Royal College of Physicians and Surgeons of Canada and a Diplomate of the American Board of Pediatrics.

Dr. Turvey provides clinical care in the specialties of Clinical Immunology, while his research program focuses on pediatric infectious and inflammatory diseases -- major causes of death and illness of children in Canada and throughout the world. Specifically, Dr. Turvey is interested in the role of innate immunity and Toll-like receptor signaling in protecting infants and young children from infectious agents, and how abnormalities of the innate immune system contribute to inflammatory diseases of childhood.

Laboratory Members

• Aaron Hirschfeld - Lab Manager
  
• Nico Marr - Post-doctoral Fellow
  
• Anthony Tang - Graduate Student

Selected Publications

1. Rzemieniak SE, Hirschfeld AF, Victor RE, Chilvers MA, Zheng D, van den Elzen P, Turvey SE (2010). Acidification-dependent activation of CD1d-restricted natural killer T cell is intact in cystic fibrosis. Immunology Jan 19. [Epub ahead of print].

2. Turvey SE, Bonilla FA, Junker AK (2009). Primary Immunodeficiency Diseases: A Practical Guide for Clinicians. Postgrad Med J 85(1010):660-6).

3. Cuvelier GDE, Schultz KR, Davis J, Hirschfeld AF, Junker AK, Tan R, Turvey SE (2009). Optimizing Outcomes of Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency. Clin Immunol, 131(2):179-88

4. Subbarao P, Becker A, Brook JR, Daley D, Mandhane PJ, Miller G, Turvey SE, Sears MR on behalf of the CHILD study investigators (2009). Epidemiology of Asthma: Risk Factors for Development. Expert Review of Clinical Immunology, 5(1): 77-95.

5. Blohmke CJ, Victor RE, Hirschfeld AF, Elias IM, Hancock DG, Lane CR, Davidson AG, Wilcox PG, Smith KD, Overhage J, Hancock RE, Turvey SE (2008). Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. Journal of Immunology; 180(11):7764-7773.

6. Burgess TST, Hirschfeld AF, Tyrrell GJ, Bettinger JA, Turvey SE (2008).  Commonly Invasive Serotypes of Streptococcus pneumoniae Trigger a Reduced Innate Immune Response Compared with Serotypes Rarely Responsible for Invasive Infection. FEMS Immunol Med Microbiol.  53(1): 136-9.

7. Afforder, N, Turvey SE (2008). Book Review “Toxic Exposures: Contested Illnesses and the Environmental Health Movement”, by Phil Brown. Osgoode Hall Law Journal, 46(2): 427-433.

8. Turvey SE, Speert DP (2007) Recurrent Systemic Pneumococcal Disease and IRAK4-Deficiency. Pediatric Infectious Disease Journal 26:1074.

9. Paulus SC, Hirschfeld AF, Victor RE, Thomas E, Brunstein J, Turvey SE (2007). Common Human Toll-like Receptor 4 Polymorphisms—Role in Susceptibility to Respiratory Syncytial Virus Infection and Functional Immunological Relevance. Clinical Immunology; 123(3):252-257.

10. Hirschfeld AF, Bettinger JA, Victor RE, Davidson DJ, Currie AJ, Ansermino JM, Scheifele DW, Orange JS, Turvey SE (2007). Prevalence of Toll-like Receptor Signalling Defects in Apparently Healthy Children Who Developed Invasive Pneumococcal Infection. Clinical Immunology; 122(3):271-278.

11. Hirschfeld AF, Jiang R, Robinson WP, McFadden DE, Turvey SE. (2007) Toll-Like Receptor 4 Polymorphisms and Idiopathic Chromosomally-Normal Miscarriage. Human Reproduction, 22:440-443.

12. Cohen L, Hirschfeld AF, Junker AK, Davis J, Turvey SE (2006). Detection of a novel nonsense mutation in the interleukin 2 receptor, gamma gene causing X-linked severe combined immunodeficiency. Annals of Allergy, Asthma and Immunology, 96(4):632

13. Nishio J, Gaglia J, Turvey SE, Campbell P, Benoist C, Mathis D (2006). Islet recovery rather than splenocyte transdifferentiation in the reversal of type 1 diabetes. Science, 311:1775-8.

14. Turvey SE, Hawn TR (2006). Towards Subtlety: Understanding the Role of Toll-like Receptor Signaling in Susceptibility to Human Infections. Clinical Immunology, 120(1):1-9.

15. Turvey SE, Swart E; Denis MC, Mahmood U, Benoist C, Weissleder R, Mathis D. (2005). Non-invasive imaging of type 1 diabetes and its reversal. Journal of Clinical Investigation, 115:2454-2461.